A personalized, human-centered approach to drug discovery and development has largely remained an unfulfilled promise. But after COVID-19 shed a light on disparities in health equity and access, digital is reshaping the biopharma industry: from pre-clinical data analysis to massive telemedicine growth to advancing diversity in clinical trial enrollment. Technologies like AI/ML combined with remote research and decentralized clinical trials help address health inequities and faster delivery of life-saving medicines to patients who need them most. This panel explores how rethinking the entire end-to-end drug development process drives greater speed, access, and equity. The panelists will also discuss ways to advance the industry through strategic partnerships.